COPD: should we go for GOLD?
In 2010, the National Institute for Health and Care Excellence (NICE) guidelines for chronic obstructive pulmonary disease (COPD) gave a guideline for therapeutic interventions in terms of the best evidence on the medications for COPD that were available at the time. This has been a useful guide since then; however, because the evidence was condensed into an algorithm for ease of use, the evidence behind the algorithm has not always been considered. Many of the COPD patients have been inadvertently placed on maximal therapies, known as triple therapy, involving a long-acting muscarinic agent and a combination inhaler containing a long-acting beta agonist and inhaled corticosteroid--all in spite of minimal symptoms, preserved lung function and few exacerbations. Here, Scullon looks at some of the issues since the NICE guidelines were published and determines whether the guidelines from the Global Initiative for Chronic Obstructive Lung Disease should be included in considering treatment options..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
British journal of nursing - 24(2015), 20, Seite 1024-1025 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scullion, Jane E [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
Chronic obstructive pulmonary disease |
| doi: |
10.12968/bjon.2015.24.20.1024 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1963447603 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1963447603 | ||
| 003 | DE-627 | ||
| 005 | 20230513002751.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.12968/bjon.2015.24.20.1024 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1963447603 | ||
| 035 | |a (DE-599)GBVOLC1963447603 | ||
| 035 | |a (PRQ)c2258-3cab1e8899d856a2a2458335245ec2006ff09afa49ff5a25fc5922d236eb52140 | ||
| 035 | |a (KEY)0016989720150000024002001024copdshouldwegoforgold | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ZDB |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Scullion, Jane E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COPD: should we go for GOLD? |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a In 2010, the National Institute for Health and Care Excellence (NICE) guidelines for chronic obstructive pulmonary disease (COPD) gave a guideline for therapeutic interventions in terms of the best evidence on the medications for COPD that were available at the time. This has been a useful guide since then; however, because the evidence was condensed into an algorithm for ease of use, the evidence behind the algorithm has not always been considered. Many of the COPD patients have been inadvertently placed on maximal therapies, known as triple therapy, involving a long-acting muscarinic agent and a combination inhaler containing a long-acting beta agonist and inhaled corticosteroid--all in spite of minimal symptoms, preserved lung function and few exacerbations. Here, Scullon looks at some of the issues since the NICE guidelines were published and determines whether the guidelines from the Global Initiative for Chronic Obstructive Lung Disease should be included in considering treatment options. | ||
| 650 | 4 | |a Regulars | |
| 650 | 4 | |a Medical treatment | |
| 650 | 4 | |a Evidence-based nursing | |
| 650 | 4 | |a Guidelines | |
| 650 | 4 | |a Chronic obstructive pulmonary disease | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of nursing |d London : MA Healthcare, 1992 |g 24(2015), 20, Seite 1024-1025 |w (DE-627)170869229 |w (DE-600)1119191-0 |w (DE-576)491125011 |x 0966-0461 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2015 |g number:20 |g pages:1024-1025 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.12968/bjon.2015.24.20.1024 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26559107 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1751185749 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_164 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 24 |j 2015 |e 20 |h 1024-1025 | ||